EN DE
STOCK COMPARISON

Cedergrenska AB vs Fredun Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how Cedergrenska AB (CEDER) and Fredun Pharmaceuticals (FREDUN) compare, as of Aug 11, 2026.

As of Aug 11, 2026, Fair Value Calculator sees Fredun Pharmaceuticals as the more attractively valued of the two: Cedergrenska AB trades at SEK 46.10 versus a fair value of SEK 35.66 (-23%), while Fredun Pharmaceuticals trades at ₹1,218 versus ₹2,155 (+77%).
Cedergrenska AB
CEDER.ST · SEK · Consumer Discretionary
-23%
upside to fair value
overvalued
PriceSEK 46.10
Fair ValueSEK 35.66
Quality70/100
Fredun Pharmaceuticals
FREDUN.BSE · INR · Healthcare
+77%
upside to fair value
undervalued
Price₹1,218
Fair Value₹2,155
Quality33/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Cedergrenska ABFredun Pharmaceuticals
Valuation
6.5×P/E (TTM)42.2×
0.04×P/S (TTM)2.23×
0.36×P/B5.03×
EV/EBITDA15.5×
3.9%Dividend yield0.0%
SEK 1.90Dividend per share₹0.70
Profitability
2%Net margin5%
5%Operating margin12%
21%Return on equity16%
10%Return on assets9%
Growth
14%Revenue growth (YoY)27%
18.9%Avg. growth/yr (3Y)32.2%
20.5%Avg. growth/yr (5Y)36.9%
Balance & size
0.50×Debt / equity0.20×
$64MMarket cap$149M
healthyGrowth qualityexpensive

Even match: 6 to 6 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Cedergrenska ABof which business quality 70 · market factors 66 Fredun Pharmaceuticalsof which business quality 35 · market factors 44
ProfitabilityMargins and returns on capital today
61
48
Quality GrowthAre margins and returns improving?
66
73
CashflowEarnings quality: real cash, not paper profit
64
5
Fin. StrengthBalance sheet, leverage, solvency risk
81
57
InvestmentDisciplined investing over empire-building
68
16
Low VolatilityCalm price path (market factor)
74
43
MomentumPrice trend over the last 3–12 months (market factor)
61
39
52W MomentumDistance to the 52-week high (market factor)
67
54
Net IssuanceBuybacks instead of dilution
82
7

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Cedergrenska AB

DCF ModelsSEK 109
Earnings-BasedSEK 37.59
MultiplesSEK 41.87
Asset-BasedSEK 9.47
Growth DCFSEK 105
Economic ProfitSEK 20.13
Growth EarningsSEK 50.20

9 of 24 models see the stock below the current price.

Fredun Pharmaceuticals

Earnings-Based₹1,942
Multiples₹1,723
Asset-Based₹345
Economic Profit₹1,854
Growth Earnings₹2,535

5 of 14 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Cedergrenska AB
Bear SEK 26.75Fair Value SEK 35.66Bull SEK 44.58
SEK 46.10 = current price (white tick)
Fredun Pharmaceuticals
Bear ₹1,509Fair Value ₹2,155Bull ₹2,802
₹1,218 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Cedergrenska AB · Consumer Discretionary

Quality score70 · Top 25%
Fair value upside-23% · below median

Fredun Pharmaceuticals · Healthcare

Quality score33 · bottom 25%
Fair value upside+77% · Top 25%

Bottom line

As of Aug 11, 2026, Fair Value Calculator sees Fredun Pharmaceuticals as the more attractively valued of the two: Cedergrenska AB trades at SEK 46.10 versus a fair value of SEK 35.66 (-23%), while Fredun Pharmaceuticals trades at ₹1,218 versus ₹2,155 (+77%).

Cedergrenska AB has the higher quality score (70/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.